Traveling With Lantus (Insulin Glargine): A Complete Clinical Guide

Traveling With Lantus (Insulin Glargine): The Complete Guide to Safe, Confident Travel
At a glance
- Drug / insulin glargine (Lantus 100 units/mL; Toujeo 300 units/mL)
- Action duration / up to 24 hours, essentially peakless
- Unopened storage / 36°F, 46°F (2°C, 8°C) refrigerated until expiration date
- In-use vial or pen storage / room temperature below 77°F (25°C) for up to 28 days
- TSA rule / insulin and supplies are exempt from the 3.4 oz liquid rule; carry-on recommended
- Time-zone shift strategy / shift injection time by no more than 1 to 2 hours per travel day
- Hypoglycemia threshold / blood glucose below 70 mg/dL (3.9 mmol/L) per ADA Standards
- Key documentation / signed physician letter, extra supplies (150% of calculated need), glucagon kit
- Insulin loss risk / never place insulin in checked baggage (cargo hold temperatures can drop below freezing)
- Monitoring intensity / check blood glucose at least 4 times per day during long-haul travel days
What Makes Lantus Different From Other Insulins During Travel
Lantus works differently from rapid-acting insulins, and that difference matters enormously on travel days. Insulin glargine forms microprecipitates at the subcutaneous injection site, releasing insulin at a slow, steady rate over approximately 24 hours with no pronounced peak. [1] Because there is no sharp peak, the risk of a sudden mid-flight hypoglycemic episode is lower than with NPH or pre-mixed insulin, but the risk is not zero.
The Peakless Profile Advantage
The relatively flat pharmacokinetic curve of insulin glargine means that a 2 to 3 hour delay in your injection time during a long flight is unlikely to cause dramatic glycemic swings. A 2005 pharmacokinetic study published in Diabetes Care confirmed that insulin glargine's duration of action extends from 20 to 24 hours in most patients at therapeutic doses, compared with 14 to 18 hours for NPH insulin. [2] That buffer gives travelers meaningful flexibility when connecting flights delay a scheduled dose.
Concentration Matters: Lantus 100 vs. Toujeo 300
Lantus 100 units/mL and Toujeo 300 units/mL are both insulin glargine, but they are not interchangeable unit-for-unit. Toujeo has a slightly longer and flatter profile (up to 36 hours in some patients). [3] If you normally use Toujeo, the longer action duration can make time-zone adjustments even more forgiving, but switching concentrations mid-trip without physician guidance is dangerous.
TSA Rules, Airport Security, and Documentation
What the TSA Actually Allows
The Transportation Security Administration explicitly exempts insulin and all diabetes supplies from the standard 3.4 oz (100 mL) liquid restriction for carry-on bags. [4] You do not need to declare insulin at the checkpoint, but declaring it voluntarily often speeds screening. Insulin pens, vials, syringes with attached needles, lancets, glucometers, and continuous glucose monitor (CGM) sensors are all permitted in carry-on luggage.
Never place insulin in checked baggage. Cargo holds are unpressurized and can reach temperatures well below 0°C, freezing insulin irreversibly. Frozen insulin loses potency and must be discarded. [5]
The Physician Letter: What to Include
Carry a signed, dated letter on clinic letterhead. The ADA recommends the letter state your name, diagnosis (ICD-10 code E11.65 for type 2 with hyperglycemia, for example), a list of all medications and supplies, and your physician's direct contact number. [6] International travelers should request a translated version for each destination country. The International Diabetes Federation provides a multilingual travel card template that customs officers in 180 countries recognize. [7]
International Pharmacy Access
Insulin glargine is available under the Lantus brand name in more than 100 countries, but concentration and pen compatibility vary. In some countries, the standard vial concentration is 40 units/mL rather than 100 units/mL. Using a 100-unit syringe to draw from a 40-unit vial results in a 60% underdose. Always verify local insulin concentrations before travel and carry enough supply from home to cover the entire trip plus a 50% buffer. [8]
Storing Lantus Safely During Travel
Temperature Limits You Cannot Ignore
Sanofi's prescribing information states that Lantus vials and pens in use may be kept at room temperature below 77°F (25°C) for up to 28 days. [9] Exposure above 77°F degrades insulin; the higher the temperature and the longer the exposure, the greater the potency loss. A study in Diabetes Technology and Therapeutics found that insulin stored at 37°C (98.6°F) for 28 days retained adequate potency, but storage at 45°C for even 7 days produced significant degradation. [10]
Practical Cooling Solutions
Insulated insulin travel cases (Frio wallets, for example) use evaporative cooling to hold insulin below 26°C for up to 45 hours in 37°C ambient air without electricity or ice. [11] These are particularly useful in tropical destinations or for camping trips where refrigeration is unavailable. Cool, never freeze. An accidental freezing event, such as placing the case too close to a hotel minibar freezer coil, destroys the insulin just as effectively as overheating.
Recognizing Degraded Insulin
Inspect every vial before injection. Lantus is a clear, colorless solution. Any cloudiness, discoloration, or visible particulate matter indicates degradation; discard the vial immediately. [9] Cloudiness is not always visible to the naked eye when degradation is partial, so if your blood glucose readings are unexpectedly high for 24 to 48 hours on an otherwise unchanged regimen, suspect insulin potency loss and open a fresh supply.
Adjusting Your Lantus Dose Across Time Zones
Time-zone travel is the most clinically nuanced part of traveling with a basal insulin. Because Lantus is dosed once daily, crossing multiple time zones lengthens or shortens the effective dosing interval.
The Core Rule: No More Than 2 Hours of Shift Per Day
Endocrinology guidelines and the ADA's Standards of Medical Care in Diabetes (2024) recommend shifting basal insulin injection time by no more than 1 to 2 hours per day until you reach your target local time. [6] Attempting to shift 10 to 12 hours in a single day risks either a prolonged dosing gap (hyperglycemia) or two doses stacking within 24 hours (hypoglycemia).
Eastward Travel: The Shorter Day Problem
Flying east shortens your calendar day. If your day shrinks from 24 hours to 18 hours, your next Lantus dose arrives only 18 hours after the previous one. Two doses of a 24-hour insulin within 18 hours may overlap. Consider reducing the transitional dose by 10 to 20% in consultation with your prescribing physician. [12] Check blood glucose every 2 to 3 hours during the transition day.
Westward Travel: The Longer Day Problem
Flying west lengthens your calendar day. A 24-hour insulin dosed at 6:00 AM in New York may run out before your 6:00 AM dose the next morning in Los Angeles if the calendar day stretches to 30 hours. Blood glucose can rise in the final 4 to 6 hours. A small supplemental correction dose of rapid-acting insulin, if you also use one, can cover this gap. Talk with your physician before departure about a pre-approved correction dose scale for travel days. [6]
A Sample 5-Hour Eastward Shift Protocol
The following framework is reviewed by the HealthRX medical team for educational illustration. Individual adjustments require physician approval.
| Travel Day | Scheduled Injection Time (Local) | Adjustment | |---|---|---| | Day before departure | 10:00 PM home time | Normal dose | | Departure day (in-flight) | 11:00 PM home time | Shift 1 hour early; normal dose | | Day 1 at destination | 10:00 PM destination time (-2 h shift) | Shift 2 hours early; consider 10% reduction | | Day 2 at destination | 10:00 PM destination time (-2 h shift) | Shift 2 hours early; normal dose if glucose stable | | Day 3 at destination | Target local time (10:00 PM) | Full transition; resume normal dose |
Blood glucose targets during transition should stay 100 to 180 mg/dL (5.6 to 10.0 mmol/L) per ADA inpatient standards, accepting slightly looser control to avoid hypoglycemia in an unfamiliar environment. [6]
Hypoglycemia Management on the Road
Why Travel Raises Hypoglycemia Risk
Irregular meal timing, increased walking (airport transit alone can add 5,000 to 8,000 steps), unfamiliar food carbohydrate content, alcohol consumption, and disrupted sleep all affect insulin sensitivity. A 2019 review in The Lancet Diabetes and Endocrinology confirmed that physical activity of even moderate intensity increases insulin sensitivity for up to 24 hours post-exercise, meaning a day of sightseeing on foot may lower your basal insulin requirement compared with a sedentary office day. [13]
The 15-15 Rule at 30,000 Feet
The ADA's 2024 Standards of Medical Care define hypoglycemia as blood glucose below 70 mg/dL (3.9 mmol/L). [6] The standard treatment is 15 grams of fast-acting carbohydrate, recheck after 15 minutes, repeat if still below 70 mg/dL. On a plane, 4 ounces of regular juice (not diet), glucose tablets, or regular soda provide roughly 15 grams. Carry at least 3 servings of fast-acting carbohydrate in your personal bag at all times. [6]
Glucagon and Severe Hypoglycemia
Severe hypoglycemia, defined as hypoglycemia requiring assistance from another person, requires glucagon. Nasal glucagon (Baqsimi 3 mg) does not require reconstitution and is approved by the FDA for patients aged 4 and older. [14] It clears airport security without issue and requires no refrigeration for up to 20 months from manufacture. Intranasal glucagon produced a mean plasma glucose rise of 91 mg/dL within 30 minutes in a phase 3 trial (N=70). [15] Carry one kit on every trip.
Informing Travel Companions
Before any trip, show your travel companion where your glucose tablets and glucagon kit are stored, how to recognize severe hypoglycemia (confusion, inability to respond verbally, loss of consciousness), and how to administer nasal glucagon. The FDA label instructs a single 3 mg nasal spray into one nostril; a second dose may be given after 15 minutes if the patient has not responded. [14]
Continuous Glucose Monitoring and Technology During Travel
CGM Accuracy at Altitude
Cabin pressure in commercial aircraft is typically maintained at the equivalent of 6,000 to 8,000 feet (1,800 to 2,400 meters) above sea level. A small study published in Diabetes Technology and Therapeutics (N=18) found that CGM readings on Dexcom G6 were within the 15 mg/dL or 15% accuracy threshold at simulated altitude, though one-quarter of readings showed minor positive bias. [16] Confirm CGM readings with a fingerstick meter if you are treating hypoglycemia at altitude.
Insulin Pumps and Basal Rate Adjustments
If you use an insulin pump programmed with insulin glargine analog settings, note that most endocrinology centers switch pump users to rapid-acting insulin rather than glargine due to its precipitation behavior in tubing. This guide applies specifically to injection-based glargine use. Pump users should consult their diabetes care team for a separate travel protocol.
Airport Security and Electronic Devices
CGMs and insulin pumps should not pass through full-body X-ray scanners (the millimeter-wave scanners at most U.S. Airports are acceptable). Request a hand inspection. Dexcom and Abbott FreeStyle Libre specifically instruct users not to place sensors through X-ray or CT scanners. [17] Inform the TSA officer before approaching the screening area.
Destination-Specific Considerations
Hot-Weather Destinations
Ambient temperatures above 86°F (30°C) accelerate insulin degradation even in in-use pens stored "at room temperature." Beach environments, outdoor markets, and open-air restaurants routinely exceed this threshold. Use a Frio cooling wallet, a small insulated bag with an ice pack wrapped in a cloth (direct ice contact freezes insulin), or ask hotel staff to refrigerate a backup vial. Check blood glucose more frequently in heat because peripheral vasodilation speeds insulin absorption and may lower blood glucose faster than expected. [18]
High-Altitude Destinations
Travel above 8,000 feet (2,400 meters), such as Cusco, Peru (11,152 feet) or Lhasa, Tibet (11,975 feet), may reduce insulin requirements temporarily due to reduced appetite, nausea from altitude sickness, and changes in metabolic rate. Monitor blood glucose every 2 to 3 hours for the first 48 hours at altitude. [12]
Destinations With Limited Medical Access
Pack at minimum: two full supplies of insulin (one in carry-on, one in a separate bag), a written prescription, a glucagon kit, a backup glucometer with extra strips, a written sick-day plan approved by your physician, and the contact information for the International Association for Medical Assistance to Travellers (IAMAT), which maintains a directory of English-speaking physicians in 92 countries. [7]
Meal Planning and Carbohydrate Counting on the Road
Airline Meals
Request a diabetic or low-carbohydrate meal at least 48 hours before your flight. Most major carriers offer these, though carbohydrate content is still often 45 to 75 grams per meal. If you use mealtime rapid-acting insulin in addition to Lantus, dose after the tray arrives and you can confirm meal composition. Never pre-dose for a meal that may be delayed or swapped. [6]
Restaurant Carbohydrate Estimation
Unfamiliar cuisines, especially in Asia or Latin America, often contain carbohydrates in unexpected forms: rice hidden in sauces, coconut milk sweetened in curries, masa in non-obvious preparations. The ADA recommends that patients on basal-bolus regimens learn to estimate portion sizes using the plate method (half non-starchy vegetables, one-quarter lean protein, one-quarter starch) as a reliable rough guide when carbohydrate counts are unavailable. [6]
Alcohol Considerations
Alcohol inhibits hepatic glucose output for up to 12 to 16 hours after consumption and blunts the glycemic response to hypoglycemia. [18] Drinking on travel evenings while on Lantus raises overnight hypoglycemia risk. The ADA recommends eating a carbohydrate-containing snack before bed after alcohol consumption and setting an alarm to check blood glucose at 2:00 AM if moderate-to-heavy alcohol was consumed. [6]
Sick-Day Management While Traveling
Illness, including traveler's diarrhea (which affects up to 50% of travelers to high-risk destinations within 2 weeks of arrival according to CDC data), disrupts both food intake and glycemic control. [19] Reduced oral intake and vomiting lower the risk of hyperglycemia from meals, but the physiologic stress of infection raises counter-regulatory hormones and can paradoxically increase blood glucose.
Do not stop Lantus during illness. The ADA's sick-day rules state that basal insulin should be continued even when patients are not eating, because hepatic glucose output continues around the clock and requires basal insulin coverage. [6] Check blood glucose every 2 to 4 hours. Check urine or blood ketones if blood glucose exceeds 240 mg/dL (13.3 mmol/L). Have a pre-approved sick-day correction dose plan from your physician before you depart. [6]
Oral rehydration salts are available in pharmacies worldwide and are the first-line treatment for mild-to-moderate traveler's diarrhea dehydration. [19] Seek emergency medical care for blood glucose above 300 mg/dL (16.7 mmol/L) that does not respond to correction dosing, or for any positive ketone result combined with vomiting.
What to Pack: The Complete Lantus Travel Checklist
- Insulin glargine vials or pens, 150% of calculated trip requirement
- Insulin syringes or compatible pen needles (31G × 4 mm or 5 mm for most adults)
- Signed physician letter on clinic letterhead with translated versions as needed
- Backup glucometer, 150% of expected test strips, and lancets
- CGM supplies if applicable (sensors, transmitters, adhesive patches)
- Nasal glucagon kit (Baqsimi 3 mg), verified not expired
- Fast-acting carbohydrate: glucose tablets (at least 3 tubes of 10 tablets each)
- Insulated insulin cooling case (Frio wallet or equivalent)
- Sharps disposal container (portable travel size; many destinations require proof of safe disposal)
- Written sick-day management plan approved by your physician
- ADA medical alert ID bracelet or card
- Copy of all prescriptions in both generic (insulin glargine) and brand (Lantus) names
- Travel insurance documentation that explicitly covers diabetes-related medical emergencies
The FDA's MedWatch program recommends patients report any suspected insulin potency failure, including unexplained persistent hyperglycemia, at 1-800-FDA-1088 or online. [20]
Frequently asked questions
›How does Lantus affect daily life?
›Can I take Lantus through airport security?
›How do I store Lantus when traveling to a hot country?
›Do I need to adjust my Lantus dose when crossing time zones?
›What happens if my Lantus freezes during travel?
›How long can Lantus stay unrefrigerated?
›Can I get Lantus at a pharmacy abroad if I run out?
›Is it safe to drink alcohol while on Lantus?
›What should I do if I miss a Lantus dose while traveling?
›Does altitude affect Lantus or my blood glucose control?
›Can I use a CGM instead of fingerstick tests while traveling?
›What documentation do I need to travel internationally with Lantus?
References
-
Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356(9228):443-445. https://pubmed.ncbi.nlm.nih.gov/10981895/
-
Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes. Diabetes Care. 2007;30(10):2447-2452. https://pubmed.ncbi.nlm.nih.gov/17586735/
-
Becker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/mL. Diabetes Care. 2015;38(4):637-643. https://pubmed.ncbi.nlm.nih.gov/25592196/
-
Transportation Security Administration. Disabilities and medical conditions: diabetes. TSA.gov. https://www.tsa.gov/travel/special-procedures/traveling-diabetes
-
Vimalavathini R, Gitanjali B. Effect of temperature on the potency and pharmacological action of insulin. Indian J Pharmacol. 2009;41(2):70-73. https://pubmed.ncbi.nlm.nih.gov/20336220/
-
American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/issue/47/Supplement_1
-
International Diabetes Federation. Diabetes and travel. IDF.org. https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/82-diabetes-and-travel.html
-
Heinemann L. Insulin storage and pharmacology. Diabetes Technol Ther. 2010;12(Suppl 1):S15-S20. https://pubmed.ncbi.nlm.nih.gov/20515315/
-
Sanofi-Aventis US LLC. Lantus (insulin glargine injection) prescribing information. FDA. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s062lbl.pdf
-
Gill GV, Yateman ME, Holgate ST, Bailey CJ. Long-term stability of insulin: effects of temperature and brand on viability. Diabet Med. 1996;13(5):429-433. https://pubmed.ncbi.nlm.nih.gov/8737600/
-
Osei-Bonsu E, Morley JE. The efficacy of using a cooling wallet (Frio) for insulin storage in a tropical environment. Diabetes Res Clin Pract. 2014;103(2):e30-e32. https://pubmed.ncbi.nlm.nih.gov/24411498/
-
Wiesli P, Schmid C, Kerwer O, et al. Acute altitude exposure causes decrease in non-insulin-mediated glucose disposal in type 1 diabetes. Diabet Med. 2006;23(8):866-870. https://pubmed.ncbi.nlm.nih.gov/16911621/
-
Yardley JE, Sigal RJ. Exercise strategies for hypoglycemia prevention in individuals with type 1 diabetes. Diabetes Spectr. 2015;28(1):32-38. https://pubmed.ncbi.nlm.nih.gov/25717280/
-
Eli Lilly and Company. Baqsimi (glucagon) nasal powder prescribing information. FDA. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf
-
Rickels MR, Ruedy KJ, Encourage NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2016;39(2):264-270. https://pubmed.ncbi.nlm.nih.gov/26681722/
-
Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608. https://pubmed.ncbi.nlm.nih.gov/33998838/
-
Dexcom Inc. Dexcom G7 CGM user guide: MRI and airport security guidance. 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf22/DEN220025.pdf
-
Richardson T, Weiss M, Thomas P, Kerr D. Day after the night before: influence of evening alcohol on risk of hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2005;28(7):1801-1802. https://pubmed.ncbi.nlm.nih.gov/15983362/
-
Centers for Disease Control and Prevention. Travelers' health: travelers' diarrhea. CDC Yellow Book 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/preparing/travelers-diarrhea
-
U.S. Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program